Ibrutinib as salvage therapy in mantle cell lymphoma with central nervous system involvement in a pretreated unfit patient.

about

Ibrutinib as salvage therapy in mantle cell lymphoma with central nervous system involvement in a pretreated unfit patient.

Item

http://www.wikidata.org/entity/Q50092725

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Ibrutinib as salvage therapy i ...... in a pretreated unfit patient.

@en

Ibrutinib as salvage therapy i ...... in a pretreated unfit patient.

@nl

type

Item

label

Ibrutinib as salvage therapy i ...... in a pretreated unfit patient.

@en

Ibrutinib as salvage therapy i ...... in a pretreated unfit patient.

@nl

prefLabel

Ibrutinib as salvage therapy i ...... in a pretreated unfit patient.

@en

Ibrutinib as salvage therapy i ...... in a pretreated unfit patient.

@nl

P1476

Ibrutinib as salvage therapy i ...... in a pretreated unfit patient

@en

P2093

Amalia De Renzo

http://www.w3.org/2001/XMLSchema#string

Fabiana Cacace

http://www.w3.org/2001/XMLSchema#string

Fabio Trastulli

http://www.w3.org/2001/XMLSchema#string

Fabrizio Pane

http://www.w3.org/2001/XMLSchema#string

Giulia Scalia

http://www.w3.org/2001/XMLSchema#string

Mara Memoli

http://www.w3.org/2001/XMLSchema#string

Marianna Notarangelo

http://www.w3.org/2001/XMLSchema#string

Orsola Vitagliano

http://www.w3.org/2001/XMLSchema#string

Stefania Leone

http://www.w3.org/2001/XMLSchema#string

P2860

Mantle cell lymphoma: evolving management strategies

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results.

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma.

High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.

Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse

Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.

Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: res

Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network.

P304

1734-1737

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/10428194.2017.1387910

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Ciro Gabriele Mainolfi

P577

2017-10-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29019439

http://www.w3.org/2001/XMLSchema#string